QureTech Bio Announces the Appointment of Markus Thor as New CEO
September 3, 2024
QureTech Bio, a biotechnology company developing novel antibiotics and anti-infectives, today announced that Markus Thor has been appointed as the new Chief Executive Officer, effective September 1, 2024.
Markus Thor brings 30 years of experience from private and public pharmaceutical industry and biotech. He has a proven track record of successful leadership and business development in R&D focused biotech companies within a range of therapeutic areas. Previous roles include Chief Business Officer at XNK Therapeutics AB, Chief Business Officer at Kancera AB and Vice President & Head of Business Development at Biovitrum AB. He holds an MSc in Chemistry from Umeå University and an MBA from Stockholm School of Economics.
Markus Thor replaces Helén Fält who is leaving upon her own request and will now start a new position as Commercial Manager at Apotek Produktion & Laboratorier (APL).
“We are delighted to welcome Markus as the new CEO of QureTech Bio. He has the vision, expertise, and leadership skills to take the company to the next level of growth and success. We are confident that he will build on the strong foundation that Helén has established and lead QureTech Bio to achieve its full potential. We are also very grateful for everything that Helén has done for the company and wish her the best of luck with her new position,” says Lennart Hansson, Chairman of the Board of QureTech Bio.
Markus Thor on his new assignment:
“I am honored and excited to join QureTech Bio, a company that is at the forefront of developing new and much needed solutions for the global health challenge of antimicrobial resistance. I look forward to working with the team, the board, and our partners to advance the company’s pipeline into the clinical stage and bring novel therapies to patients in need”.
Contact
Lennart Hansson, Chairman of the Board
E-post: lennart@ignitus.se
Mobil: +46 70-631 00 31
Web: www.quretech.com
About
QureTech Bio AB is a pharmaceutical development company with a focus on developing new solutions to combat disease-causing bacteria and thereby contribute with new alternatives to one of our times’ greatest threats to modern healthcare, antimicrobial resistance (AMR). The company’s lead program is focused on developing a new class of antibiotics, called GmPcides, that are effective against multidrug resistant Gram-positive bacteria. QTB is located in Umeå, which is one of Sweden’s prominent life science clusters.